On June 6, Pfizer (PFE) announced that it would invest ~$600 million in biotechnology and emerging growth companies through Pfizer Ventures, its venture investment vehicle.
The chart above shows the key highlights of Pfizer Ventures’ recent developments.
Pfizer also announced its plans to leverage its expertise in investing, business development, and drug discovery and development at Pfizer Ventures, making it a leader in venture capital investing.
From these funds, the company plans to invest 25%, the equivalent of $150 million, in early-stage neuroscience companies. As per the company’s press release, its initial areas of investment in neuroscience companies will include neuroinflammation, neurodegeneration, and neurometabolic disorders.
At present, there are six neuroscience companies in which Pfizer Ventures invests: Aquinnah, Autifony, MindImmune, Neuronetics, Cortexyme, and MISSION.
Apart from neuroscience, Pfizer Ventures also plans to invest in therapeutic areas such as oncology, rare diseases, inflammation and immunology, and vaccines.
About Pfizer Ventures
The existing portfolio of Pfizer Ventures includes over 40 companies and ~$500 million in investments. The addition of $600 million increases the business’s total assets under management to ~$1.1 billion. A few of Pfizer Ventures’ recent investments include Adapsyn Bioscience, Complexa, DIR Technologies, Jnana Therapeutics, and eFFECTOR Therapeutics.
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!